Next generation predictive biomarkers for immune checkpoint inhibition

PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?

(2016) Alain C. Borczuk et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

(2016) Michael D. Iglesia et al.   JNCI-Journal of the National Cancer Institute

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer

(2016) Yusuke Inoue et al.   Oncotarget

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

(2016) Michael D. Iglesia et al.   JNCI-Journal of the National Cancer Institute

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

(2015) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Abstract P5-04-03: Deconvoluting immune cell populations using ‘in silico flow cytometry’ with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC

(2015) Shaveta Vinayak et al.   CANCER RESEARCH

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

(2015) Razelle Kurzrock et al.   CELL CYCLE

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

(2015) I. C. van Gool et al.   CLINICAL CANCER RESEARCH

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses

(2015) Norman Woller et al.   MOLECULAR THERAPY

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma

(2015) Patcharee Ritprajak et al.   ORAL ONCOLOGY

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

(2015) Ninh M. La-Beck et al.   PHARMACOTHERAPY

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies

(2015) Sergio Bracarda et al.   SEMINARS IN ONCOLOGY

High-resolution analysis of the human T-cell receptor repertoire

(2015) Eliana Ruggiero et al.   Nature Communications

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology

(2015) Sandip Pravin Patel et al.   Oncotarget

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study

(2015) Colm Keane et al.   Lancet Haematology

An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy

(2015) Neeraj Lal et al.   OncoImmunology

Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma

(2015) Simona Partlová et al.   OncoImmunology

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors

(2015) Mark Ayers et al.   Journal for ImmunoTherapy of Cancer

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

(2015) Lars Henning Schmidt et al.   PLoS One

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms

(2015) Jennifer J. Wheler et al.   Oncotarget

Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations

(2014) J. Wheler et al.   CANCER RESEARCH

Microsatellite Instability Detection by Next Generation Sequencing

(2014) S. J. Salipante et al.   CLINICAL CHEMISTRY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

(2013) S. Lyford-Pike et al.   CANCER RESEARCH

Computational deconvolution: extracting cell type-specific information from heterogeneous samples

(2013) Shai S Shen-Orr et al.   CURRENT OPINION IN IMMUNOLOGY

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating microRNA-21 as noninvasive predictive biomarker for response in cancer immunotherapy

(2013) Zhiyu Wang et al.   MEDICAL HYPOTHESES

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Molecular Signature of Smoking in Human Lung Tissues

(2012) Y. Bosse et al.   CANCER RESEARCH

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas

(2012) Claire Palles et al.   NATURE GENETICS

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum microRNAs as non-invasive biomarkers for cancer

(2010) Jan C Brase et al.   Molecular Cancer